This report is required by law (7 USC 2143). Failure to report according to the regulations can result in an order to cease and desist and to be subject to penalties as provided for in Section 21!

See attached form for additional information.

DEC 13 2005

Interagency Report Control No.:

UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

ANNUAL REPORT OF RESEARCH FACILITY

(TYPE OR PRINT)

1. CERTIFICATE NUMBER: 23-R-0012

CUSTOMER NUMBER: 286

FORM APPROVED
OMB NO. 0579-0036

Glaxo Smith Kline
709 Swedeland Road, P.O. Box 1539
King Of Prussia, PA 19406

Telephone: (610) -270-4800

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, or experimentation, or held for these purposes. Attach additional sheets if necessary)

FACILITY LOCATIONS (Sites) - See Atached Listing

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY **(Attach additional sheets if necessarv or use APHIS Form 7023A)**

A. Animals Covered By The Animal Welfare Regulations	B. Number of animal being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not ye used for such purposes.	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use o pain-relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals an for which appropriate anesthetic, analgesic, or tranquilizing drugs were used.	E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for wh the use of appropriate anesthetic, analgesic, or tranquiliz drugs would have adversely affected the procedures, res or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reasc such drugs were not used must be attached to this report	F. TOTAL NUMBER OF ANIMALS (COLUMNS C + D + E)
4. Dogs	70	461	373	2	836
5. Cats	36	88	0	0	88
6. Guinea Pigs	51	584	426	240	1250
7. Hamsters	0	0	69	0	69
8. Rabbits	0	748	527	0	1275
9. Non-human Primates	11	426	712	0	1138
10. Sheep	0	0	0	0	0
11. Pigs	0	0	0	0	0
12. Other Farm Animals	0	0	0	0	0
13. Other Animals Ferrets	5	0	0	49	49

ASSURANCE STATEMENTS

1) Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anestetic, analgesic, and tranquilizing drugs, prior to, during, and following actual rese teaching, testing, surgery, or experimentation were followed by this research facility.

2) Each principal investigator has considered alternatives to painful procedures.

3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and ap Institutional Animal Care and Use Committee (IACUC). **A summary of all such exceptions is attached to this annual report.** In addition to identifying the IACUC-approved exceptions, this summary inc brief explanation of the exceptions, as well as the species and number of animals affected.

4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use.

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional Official)

b6, b7C

TE SIGNED
/21/05

APHIS FORM 7023
(AUG 91)

(Replaces VS FORM 18-23 (OCT 88), which is obsolete.)

Development

NOV 23 2005

DEC 13 2005

APHIS Form 7023 Site List

The following sites have been reported by the facility.

Registration Number:	23-R-0012
Customer Number:	286
Facility:	GlaxoSmithKline 709 Swedeland Road P.O. Box 1539 King of Prussia, PA 19406-0939 (610)270-4800

GlaxoSmithKline (Valley Forge Area)
709 Swedeland Road
King of Prussia, PA



NOV 2 3 2005

DEC 13 2005

GlaxoSmithKline

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel. 919 483 2100
www.gsk.com

TO: ***B. Walton***
Attending Veterinarian

FROM: [redacted]

SUBJECT: ***Animal Care Regulations and Standards***

DATE: ***1 November 2005***

During the period from October 1, 2004 to September 30, 2005 there were no exceptions to the regulations or standards identified by the IACUC at our site in [redacted] This includes having no exceptions to our exercise plan and all nonhuman primates participated in the environmental enrichment program.

DEC 13 2005

NOV 23 2005

GlaxoSmithKline

GlaxoSmithKline
709 Swedeland Road
P.O. Box 1539
King of Prussia, PA
19406-0939

Tel. 610 270 4800
Fax. 610 270 7777
www.gsk.com

TO: ***L. Meunier***
Attending Veterinarian

FROM: [redacted]

SUBJECT: ***Animal Care Regulations and Standards***

DATE: ***27-October-2005***

During the period from October 1, 2004 to September 30, 2005 there were no exceptions to the regulations or standards identified by the IACUC at our sites in [redacted] Pennsylvania. This includes having no exceptions to our exercise plan and all nonhuman primates participated in the environmental enrichment program.

Explanation of Animals Listed in Column E
2004-2005 USDA Annual Report for Registration Number 23-R-0012

Dogs

Two (2) dogs are listed in Column E. Both dogs were part of Safety Assessment studies that were conducted in accordance with US Food and Drug Administration Good Laboratory Practice for Nonclinical Laboratory Studies, 21 CRF Part 58.

Toxicity Study for development of a novel anti-cancer compound

Two (2) dogs on this study developed vomiting, depression, and weight loss after being dosed with a novel anti-cancer compound. In each case supportive care was given. This included fluid therapy, parental nutritional supplements, alternative feeding patterns and novel foods. Administration of additional therapy such as anti-emetics or analgesics would have interfered with the documentation of the disease process for drug safety assessment.

Ferrets

Forty nine (49) ferrets are listed in Column E.

Studies for development of novel anti-emetic compounds for the treatment of chemotherapy induced emesis

Forty nine/fifty four (49) ferrets were involved in studies to evaluate novel anti-emetic compounds. Animals were given novel anti-emetic compounds plus vehicle or vehicle alone then given a known agent that causes vomiting. Some animals were used as controls, but the majority of ferrets were drug-treated. All animals showed mild to moderate signs of sedation (quiet and sleeping) within the first few hours of dosing and controls did show signs of emesis (vomiting and/or retching). Signs of emesis were not seen routinely in animals treated with novel anti-emetic compounds. Animals were closely monitored. Some animals exhibited anorexia and had weight loss (10-15%) by 72 hours. All animals were euthanized by the 3rd day post-dosing. Known anti-emetic compounds or analgesics were not given because of interference with study results.